A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma

Annals of Oncology

Volumn 11, Issue 1, 2000, Pages 113-114

  Halm, U ^a   Etzrodt, G ^a   Schiefke, I ^a   Schmidt, F ^a   Witzigmann, H ^a   Mossner J ^a   Berr, F ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Liposomal doxorubicin; Phase II

Indexed keywords

DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 0033950350     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008386822906     Document Type: Article

References (5)

1. Gabizon A, Martin F. Polyethylene glycol-coaled (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54 (Suppl 4): 15-21.
2. Ichinose K, Yamamoto M, Khoji T et al. Antitumor effect of polysaccharide coated liposomal adriamycin on AH66 hepatoma in nude mice. Anticancer Res 1998; 18: 401-4.
3. Lai CL, Wu PC, Chan GC et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-83.
4. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117-36.
5. Yeo W, Chan KK, Mukwaya G et al. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: Clinical and pharmacokinetic outcomes. Cancer Chemother Pharmacol 1999; 44: 124-30.